Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Tumor Angiogenesis Research

Executive Summary: Anlotinib hydrochloride is a next-generation small-molecule inhibitor that targets VEGFR2, PDGFRβ, and FGFR1 at nanomolar potency, yielding robust inhibition of tumor-driven angiogenesis (Lin et al., 2018). It outperforms legacy TKIs such as sunitinib, sorafenib, and nintedanib in endothelial cell migration and tube formation assays under standardized conditions. The compound demonstrates high oral bioavailability, broad tissue distribution (including the ability to cross the blood-brain barrier), and minimal systemic toxicity at preclinical doses. APExBIO provides Anlotinib (hydrochloride) as SKU C8688, supporting rigorous cancer and angiogenesis research (APExBIO). All claims are substantiated by peer-reviewed evidence and product documentation.

Biological Rationale

Angiogenesis, the process of new blood vessel formation, is critical for tumor growth and metastasis (Lin et al., 2018). Tumors secrete pro-angiogenic cytokines, notably VEGF, PDGF-BB, and FGF-2, to recruit endothelial cells and induce neovascularization. These factors act primarily through their respective tyrosine kinase receptors: VEGFR2, PDGFRβ, and FGFR1. Inhibiting these signaling pathways disrupts nutrient and oxygen supply to tumors, establishing a validated anti-tumor strategy. Multi-target tyrosine kinase inhibitors (TKIs) such as Anlotinib hydrochloride are designed to block these convergent pro-angiogenic axes, offering a rational approach to impeding cancer progression (detailed mechanism overview).

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib (hydrochloride) is a small-molecule inhibitor with nanomolar potency against VEGFR2 (IC₅₀: 5.6 ± 1.2 nM), PDGFRβ (IC₅₀: 8.7 ± 3.4 nM), and FGFR1 (IC₅₀: 11.7 ± 4.1 nM) (Lin et al., 2018). Binding to the ATP-binding pockets of these kinases, Anlotinib blocks receptor autophosphorylation and downstream ERK pathway activation. This mechanistic blockade suppresses endothelial cell proliferation, migration, and capillary-like tube formation. In cell-based assays with human EA.hy 926 endothelial cells, Anlotinib inhibits VEGF/PDGF-BB/FGF-2-induced migratory responses and network formation in a concentration-dependent manner. Additionally, the compound reduces microvessel density in ex vivo (rat aortic ring) and in vivo (chicken CAM) angiogenesis models. By targeting multiple pro-angiogenic kinases, Anlotinib minimizes compensatory signaling escape—a limitation of earlier single-target TKIs (see strategic guidance).

Evidence & Benchmarks

• Anlotinib inhibits VEGFR2, PDGFRβ, and FGFR1 with IC₅₀ values of 5.6 ± 1.2 nM, 8.7 ± 3.4 nM, and 11.7 ± 4.1 nM, respectively, in enzymatic assays (DOI).
• In EA.hy 926 cell migration and tube formation assays, Anlotinib demonstrates superior inhibition compared to sunitinib, sorafenib, and nintedanib under matched conditions (DOI).
• Oral bioavailability in rats is 28–58% and in dogs 41–77%; plasma protein binding in humans is 93% (APExBIO).
• Tissue distribution studies reveal high accumulation in lung, liver, kidney, heart, and tumor tissues, with documented blood-brain barrier permeability (DOI).
• Safety evaluations show a 14-day oral median lethal dose (LD₅₀) of 1735.9 mg/kg in rodents, with no significant organ or genetic toxicity at research doses (APExBIO).
• Peer-reviewed, side-by-side benchmarking confirms reproducible anti-angiogenic superiority over legacy TKIs (reference tool overview).

Applications, Limits & Misconceptions

Anlotinib hydrochloride is validated for research use in cellular assays investigating angiogenesis, tyrosine kinase signaling, and tumor biology. Key applications include:

• Endothelial cell migration inhibition assays (e.g., scratch/wound healing, Boyden chamber).
• Capillary-like tube formation on Matrigel or similar substrates.
• Downstream ERK pathway phosphorylation analysis (e.g., Western blot, ELISA).
• Ex vivo and in vivo angiogenesis models (rat aortic ring, chicken CAM).

For detailed mechanistic and workflow optimization, this article extends the technical depth of MolecularBeacon's overview by providing quantitative benchmarks and safety data. For strategic translational guidance, this review outlines broader clinical and research implications.

Common Pitfalls or Misconceptions

• Not a clinical or diagnostic agent: Anlotinib (hydrochloride) from APExBIO is for research use only and is not GMP-certified for human or veterinary therapeutic applications.
• Single pathway blockade is insufficient: Unlike single-target TKIs, Anlotinib’s efficacy arises from simultaneous multi-kinase inhibition; exclusive use against only one target may yield suboptimal results (DOI).
• Not universally effective in all cell types: Efficacy is documented in human endothelial cells (EA.hy 926) and select tumor models; results may not generalize to non-angiogenic systems.
• Not a pan-kinase inhibitor: Activity is selective for VEGFR2, PDGFRβ, and FGFR1; kinases outside this spectrum may not be inhibited at relevant concentrations.
• Pharmacokinetic parameters are model-dependent: Bioavailability, tissue distribution, and metabolism may vary by species, administration route, and matrix.

Workflow Integration & Parameters

Anlotinib (hydrochloride) is supplied by APExBIO (SKU C8688) with validated stability at -20°C (product page). For cell-based assays, recommended concentration ranges are 1–100 nM, with optimal effects on endothelial migration and tube formation observed at 10–50 nM. Compound is typically solubilized in DMSO at stock concentrations up to 10 mM; working dilutions should minimize vehicle content (<0.1% v/v). For signaling assays, treatment durations range from 15 minutes to 24 hours, compatible with Western blot, ELISA, or high-content imaging endpoints. For in vivo or ex vivo validation, dosing is informed by preclinical pharmacokinetics and safety—consult primary literature for species-specific regimens.

This article updates and clarifies the workflow recommendations found in this protocol guide by including recent findings on tissue distribution and safety margins.

Conclusion & Outlook

Anlotinib hydrochloride is a rigorously characterized multi-target tyrosine kinase inhibitor that advances the study of tumor angiogenesis and tyrosine kinase signaling. Its superior potency, multi-kinase specificity, and robust anti-angiogenic effects distinguish it as a best-in-class research tool. Continuous benchmarking against legacy TKIs and incorporation of updated pharmacokinetic and safety data underscore its value for preclinical and translational workflows. For further details or to acquire the validated C8688 kit, visit the official APExBIO product page.